Zalicus Inc. and Epirus Biopharmaceuticals, Inc. agreed that Zalicus stockholders will own 19% of the combined company post-merger. In addition, Dr. Mark H.N. Corrigan will serve as chairman of the company's board of directors, which will have representatives from both the existing Epirus and Zalicus boards.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 26 | |
+64.92% | 62.59B | |
-1.85% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.96% | 19.09B | |
+4.21% | 13.08B | |
+25.74% | 12.26B | |
+27.42% | 12.05B |
- Stock Market
- Equities
- EPRSQ Stock
- News EPIRUS Biopharmaceuticals, Inc.
- Epirus Biopharmaceuticals, Inc. Appoints Mark H.N. Corrigan to Board of Directors